<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H5B14FCC062744481BCB142995AEBDF7B" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 4825 IH: Marijuana Effective Drug Studies Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-01-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 4825</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180118">January 18, 2018</action-date><action-desc><sponsor name-id="B001250">Mr. Bishop of Utah</sponsor> (for himself, <cosponsor name-id="C001114">Mr. Curtis</cosponsor>, <cosponsor name-id="S001192">Mr. Stewart</cosponsor>, <cosponsor name-id="L000584">Mrs. Love</cosponsor>, <cosponsor name-id="R000606">Mr. Raskin</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="P000598">Mr. Polis</cosponsor>, and <cosponsor name-id="B000574">Mr. Blumenauer</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the <committee-name committee-id="HJU00">Committee on the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To improve medical research on marijuana.</official-title></form>
	<legis-body id="HC145338F49E846A4A16411CDA2AD14E9" style="OLC">
 <section id="HB8A9FA123900474899620162D261A382" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Marijuana Effective Drug Studies Act of 2018</short-title></quote> or the <quote><short-title>MEDS Act</short-title></quote>.</text> </section><section id="HA27F0068014B40E380E29B71DD507459" section-type="subsequent-section"><enum>2.</enum><header>Marijuana research</header> <subsection id="HB0329C12179E4CF5B2FA308EBCEA9341"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 303(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)</external-xref>) is amended—</text>
 <paragraph id="H25D1E9191C9D4DBD9157535A832C4278"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively;</text> </paragraph><paragraph id="H50A859AB7E0A4FCDAD30AF4C80BBDBC2"><enum>(2)</enum><text>by striking <quote>(f) The Attorney General</quote> and inserting <quote>(f)(1) The Attorney General</quote>;</text>
 </paragraph><paragraph id="H7FACCE61129F4706A9FB0831DBFA8EC5"><enum>(3)</enum><text>by striking <quote>Registration applications</quote> and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="H93ED16CA3AC34ACA8B919F5A7D520BDC" style="OLC"> <paragraph id="HC3CF3A3C8A564D7CB0B2B7A1F55B5E07" indent="up1"><enum>(2)</enum><text>Registration applications</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H589F47512C564A27B22C490ECFEDDFA7"><enum>(4)</enum><text>in paragraph (2), as so designated, by striking <quote>schedule I</quote> each place that term appears and inserting <quote>schedule I, except marijuana,</quote>;</text> </paragraph><paragraph id="H83497B2DB5DF4A85906EC14D06202BC4"><enum>(5)</enum><text>by striking <quote>Article 7</quote> and inserting the following:</text>
					<quoted-block display-inline="no-display-inline" id="H520B59F194EB4E6D80CCE2E42A928322" style="OLC">
 <paragraph id="H5C8FC39F58C0486B82736D8C1A971DBB" indent="up1"><enum>(4)</enum><text>Article 7</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block> </paragraph><paragraph id="H62B047EB7BF04896884FE9CFBF994DED"><enum>(6)</enum><text>by inserting before paragraph (4), as so designated, the following:</text>
					<quoted-block display-inline="no-display-inline" id="HE266DDE9B7E34EB19416B3B41B88C5D2" style="OLC">
						<paragraph id="H73CF28D9072046198063098541712C80" indent="up1"><enum>(3)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="HDA7FB5533BEA4666B7F5ADCFC596CE94"><enum>(A)</enum><text>The Attorney General shall register a practitioner to conduct research with marijuana if—</text> <clause id="H9C9CCC2D465B46679CE3B2FEE946FAB2" indent="up1"><enum>(i)</enum><text>the applicant is authorized to dispense, or conduct research with respect to, controlled substances in schedules II, III, IV, and V under the laws of the State in which the applicant practices;</text>
 </clause><clause id="HD1649B77E0864B48A79F7D615D141368" indent="up1"><enum>(ii)</enum><text>the applicant’s research protocol—</text> <subclause id="HDDACAD01876A49BBB273EA5D9AC74524"><enum>(I)</enum><text>has been reviewed and allowed by—</text>
 <item id="HD60A07826D6F4A6D85E8A19D5FDA6D4A"><enum>(aa)</enum><text>the Secretary under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>); or</text>
 </item><item id="H6F96B28093D04AAC989506BBB99498AB"><enum>(bb)</enum><text>the National Institutes of Health or another Federal agency that funds scientific research; or</text> </item></subclause><subclause id="HD0117E7029494AA8AD6821851096E373"><enum>(II)</enum><text>in the case of nonhuman research that is not federally funded, has been voluntarily submitted by the applicant to, and approved by, the National Institutes of Health; and</text>
 </subclause></clause><clause id="HF7CBD0FC587744AAA526F4785BAB7B0E" indent="up1"><enum>(iii)</enum><text>the applicant has demonstrated that there are effective procedures in place to adequately safeguard against diversion of the marijuana from legitimate medical or scientific use, in accordance with subparagraph (E).</text>
 </clause></subparagraph><subparagraph id="HC9D2C309AEB64BA5892E7839198E77C6" indent="up1"><enum>(B)</enum><text>The Attorney General shall grant an application for registration under this paragraph unless the Attorney General determines that the issuance of the registration would be inconsistent with the public interest. In determining the public interest, the following factors shall be considered:</text>
 <clause id="HDD3695D2CA32433F85598E2F9EC2376B"><enum>(i)</enum><text>The applicant's experience in dispensing, or conducting research with respect to, controlled substances.</text>
 </clause><clause id="H7A9B12E723104DE4B2870DFCCF24276B"><enum>(ii)</enum><text>The applicant's conviction record under Federal or State laws relating to the manufacture, distribution, or dispensing of controlled substances.</text>
 </clause><clause id="H15B10C11FFC648B790931E12BD52060C"><enum>(iii)</enum><text>Compliance with applicable State, Federal, or local laws relating to controlled substances.</text> </clause><clause id="H016602C034A1423DB311C2689965924C"><enum>(iv)</enum><text>Such other conduct by the applicant that may threaten the public health and safety.</text>
 </clause></subparagraph><subparagraph id="HF335ECC3CBEF46728C2BC11BDCB7979F" indent="up1"><enum>(C)</enum><text>Not later than 90 days after the date of enactment of this paragraph, for purposes of subparagraph (A)(ii)(II), the National Institutes of Health shall establish a process that—</text>
 <clause id="HE6C3A2EEADBB4797A366A1B37708F25D"><enum>(i)</enum><text>allows a researcher to voluntarily submit the research protocol of the researcher for review and approval; and</text>
 </clause><clause id="HF9C1AE26FB2C4075847EE73BDE893834"><enum>(ii)</enum><text>provides a researcher described in clause (i) with a decision not later than 30 days after the date on which the research protocol is submitted.</text>
								</clause></subparagraph><subparagraph id="H8221AC7B5A804EA2BA5FE18819EA6D9D" indent="up1"><enum>(D)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="HFF10DE6E0F784D53BBDFC8B790174D48"><enum>(i)</enum><text>Not later than 60 days after the date on which the Attorney General receives a complete application for registration under this paragraph, the Attorney General shall—</text>
 <subclause id="H63C03BFCAE0145039A012C2902111E07" indent="up1"><enum>(I)</enum><text>approve the application; or</text> </subclause><subclause id="H80102CDD679B49D5BA3DE3340FF2F5D2" indent="up1"><enum>(II)</enum><text>serve an order to show cause upon the applicant in accordance with section 304(c).</text>
 </subclause></clause><clause id="HB6788BC27CF945EAACB58B1C5DB793C9" indent="up1"><enum>(ii)</enum><text>For purposes of clause (i), an application shall be deemed complete when the applicant has submitted documentation showing that the requirements under subparagraph (A) are satisfied.</text>
								</clause></subparagraph><subparagraph id="H8385528422C14F1CB33EAD0E22C3BF67" indent="up1"><enum>(E)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H7B1CFB6FC19C4632AECC9E92611E0238"><enum>(i)</enum><text>A researcher registered under this paragraph shall store marijuana to be used in research in a securely locked, substantially constructed cabinet.</text>
 </clause><clause id="H3CF0B837F9C343848E44B269F5F15A3F" indent="up1"><enum>(ii)</enum><text>Any other security measures required by the Attorney General under this paragraph to safeguard against diversion shall be consistent with those required for practitioners conducting research on other controlled substances in schedules I and II that have a similar risk of diversion and abuse.</text>
								</clause></subparagraph><subparagraph id="H77AE8412006C4256BC36845E64DC4563" indent="up1"><enum>(F)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="HC18BD203CC0B401AAE07943A68F700C5"><enum>(i)</enum><text>If the Attorney General grants an application for registration under this paragraph, the applicant may amend or supplement the research protocol without reapplying if the applicant does not—</text>
 <subclause id="H252E9760989E4259A55366986BFB428B" indent="up1"><enum>(I)</enum><text>change the type of drug, the source of the drug, or the conditions under which the drug is stored, tracked, or administered; or</text>
 </subclause><subclause id="H0321614B26D745C195F78D70995109A4" indent="up1"><enum>(II)</enum><text>otherwise increase the risk of diversion.</text> </subclause></clause><clause id="H7B95F6B1B5D34538AFEFBF0D81DDE7AD" indent="up1"><enum>(ii)</enum><text>If an applicant amends or supplements the research protocol under clause (i), the applicant shall, in order to renew the registration under this paragraph, provide notice to the Attorney General of the amended or supplemented research protocol in the applicant's renewal materials.</text>
								</clause><clause id="HF1C00365D4EB470F9474B8E88ABC9FD8" indent="up1"><enum>(iii)</enum>
 <subclause commented="no" display-inline="yes-display-inline" id="HE79B01FF3D1747098EFB8A861A0019EC"><enum>(I)</enum><text>If an applicant amends or supplements the research protocol in a manner that involves a change to the type of drug, the source of the drug, or conditions under which the drug is stored, tracked, or administered or otherwise increases the risk of diversion, the applicant shall provide notice to the Attorney General not later than 30 days before proceeding on such amended or supplemental research protocol.</text>
 </subclause><subclause id="H807F708497D74578A3271130EEB8D072" indent="up1"><enum>(II)</enum><text>If the Attorney General does not object during the 30-day period following a notification under subclause (I), the applicant may proceed with the amended or supplemental research protocol.</text>
 </subclause></clause><clause id="H49EC96FFAB2E4845B3EEF506B5D2D838" indent="up1"><enum>(iv)</enum><text>The Attorney General may object to an amended or supplemental research protocol under clause (i) or (iii) if additional security measures are needed to safeguard against diversion or abuse.</text>
 </clause></subparagraph><subparagraph id="H93246EDD00AD4C818FE779676C5D4560" indent="up1"><enum>(G)</enum><text>Article 28 of the Single Convention on Narcotic Drugs shall not be construed to prohibit, or impose additional restrictions upon, research involving marijuana that is conducted in accordance with this paragraph and other applicable provisions of this title.</text>
 </subparagraph><subparagraph id="HE4D97FF6DAD7493E832DB498E59BF58D" indent="up1"><enum>(H)</enum><text>If marijuana or a compound of marijuana is listed on a schedule other than schedule I—</text> <clause id="H4A7933733A244FCF8281A17E353F67B7"><enum>(i)</enum><text>the provisions of this subsection that apply to research with a controlled substance in the applicable schedule shall apply to research with marijuana or that compound, as applicable; and</text>
 </clause><clause id="H479C407CDB9547F48C15E30404D9443C"><enum>(ii)</enum><text>subparagraphs (A) through (G) of this paragraph shall not apply to research with marijuana or that compound, as applicable.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HB3A83E30763D4851ADE49EF34B4B362C"><enum>(b)</enum><header>Conforming amendment</header><text>Section 102(16) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802(16)</external-xref>) is amended by inserting <quote>or <term>marijuana</term></quote> after <quote>The term <term>marihuana</term></quote>.</text> </subsection></section><section id="H1A285FC5EEEF4BD08E4430BCCDD8295F" section-type="subsequent-section"><enum>3.</enum><header>Manufacturing of marijuana for clinical use</header><text display-inline="no-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="HB8C00096B5B540278532D8776EE8F62B" style="OLC">
				<subsection id="HCFBC7C3C419149AF924D79410732A0B8"><enum>(k)</enum><header>Registration of persons To manufacture and distribute marijuana</header>
 <paragraph id="H98ECDC5908F64B1C99FB6CCBA9E92EEA"><enum>(1)</enum><header>Manufacture and distribution for use in research</header><text>The Attorney General shall register an applicant to manufacture or distribute marijuana on behalf of the Federal Government to the extent that the marijuana is intended to be used exclusively for legitimate research and scientific uses, in accordance with the applicable requirements under subsection (a) or (b) for registration of manufacturers or distributors of controlled substances in schedule I or II.</text>
 </paragraph><paragraph id="HF017C06B5002449B8A09F3AA8A8C5BEE"><enum>(2)</enum><header>Manufacture and distribution for commercial production of FDA-approved drugs</header><text>The Attorney General shall register an applicant to manufacture or distribute marijuana on behalf of the Federal Government exclusively for the purpose of commercial production of a drug containing or derived from marijuana that is approved by the Secretary under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), in accordance with the applicable requirements under subsection (a) or (b) of this section for registration of manufacturers or distributors of controlled substances in schedule I or II.</text>
 </paragraph><paragraph id="H676C809DC1BF44C28F4EFA1649768FF5"><enum>(3)</enum><header>No limit on number of manufacturers and distributors</header><text>The Attorney General shall not impose a limit on the number of applicants eligible to be registered under paragraph (1) or (2).</text>
 </paragraph><paragraph id="H116D3406C3FD40CE9D3415573F30AFB6"><enum>(4)</enum><header>Timing</header><text>Not later than 30 days after the date on which the Attorney General receives an application for registration under paragraph (1) or (2), the Attorney General shall—</text>
 <subparagraph id="HEBEEDD13EC7A40D7BCFB359F8420CD38"><enum>(A)</enum><text>grant the application; or</text> </subparagraph><subparagraph id="HD2951F1F7FA0440AA99917A5D314443B"><enum>(B)</enum><text>serve an order to show cause upon the applicant in accordance with section 304(c).</text>
 </subparagraph></paragraph><paragraph id="HA8A854223DED4A7E87D87EA00199B38E"><enum>(5)</enum><header>Determination of supply</header><text>In considering the factors under subsection (a) or (b), as applicable, for the purposes of registering an applicant eligible under paragraph (1) or (2) of this subsection, the Attorney General shall consider the demand from researchers for an adequate and uninterrupted supply of specific strains of marijuana and for marijuana grown pursuant to specific manufacturing processes.</text>
					</paragraph><paragraph id="HC9F0005684E647E785D4773D56137E65"><enum>(6)</enum><header>Relation to the Single Convention on Narcotic Drugs</header>
 <subparagraph id="H55A8961E0D794973B2A154A6F92FF9C9"><enum>(A)</enum><header>Constructive possession and control</header><text>The registration of manufacturers and distributors of marijuana under paragraphs (1) and (2) shall constitute constructive possession and control by the Federal Government for the purposes of the obligations under the Single Convention on Narcotic Drugs.</text>
 </subparagraph><subparagraph id="H8BAC057BE5CB42108C31274DF271EF8B"><enum>(B)</enum><header>Article 28</header><text>Article 28 of the Single Convention on Narcotic Drugs shall not be construed to prohibit, or impose additional restrictions upon, the manufacturing of marijuana that is conducted in accordance with paragraph (1) or (2), as applicable, and other applicable provisions of this title.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section id="H191454BC2867453AACC4DF38211A705C" section-type="subsequent-section"><enum>4.</enum><header>Good manufacturing practices</header><text display-inline="no-display-inline">Not later than 180 days after the date of enactment of this Act, the National Institute for Drug Abuse shall develop and publish recommendations for good manufacturing practices for growing and producing marijuana (as defined in section 102 of the Controlled Substance Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>), as amended by this Act) for research.</text>
 </section><section id="H085676C306E54AFD9A752014DF31C86B" section-type="subsequent-section"><enum>5.</enum><header>Quotas</header><text display-inline="no-display-inline">Section 306(e) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/826">21 U.S.C. 826(e)</external-xref>) is amended in the third sentence by striking <quote>exceeds the aggregate of the quotas of all registrants under this section</quote> and inserting <quote>should be increased to meet the changing medical, scientific, and industrial needs for the controlled substance</quote>.</text>
 </section><section id="H89B61BA646674462BFD0E136C5A241DA" section-type="subsequent-section"><enum>6.</enum><header>Termination of interdisciplinary review process for non-NIH-funded researchers</header><text display-inline="no-display-inline">The Secretary of Health and Human Services may not—</text> <paragraph id="H7CD52C16AB704ACE8EB4CF508ABA3A33"><enum>(1)</enum><text display-inline="yes-display-inline">reinstate the Public Health Service interdisciplinary review process described in the guidance entitled <quote>Guidance on Procedures for the Provision of Marijuana for Medical Research</quote> (issued on May 21, 1999); or</text>
 </paragraph><paragraph id="H604C74E8F43545B9B2784CCD2A5C51BE"><enum>(2)</enum><text display-inline="yes-display-inline">create an additional review of scientific protocols that is conducted only for research on marijuana (as defined in section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>), as amended by section 2(b)) other than the review of research protocols performed at the request of a researcher conducting nonhuman research that is not federally funded, in accordance with section 303(f)(3)(A)(ii)(II) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)(3)(A)(ii)(II)</external-xref>), as amended by section 2(a).</text>
			</paragraph></section></legis-body></bill>


